Sanyou Medical announced that the company plans to use its own capital to jointly invest in a new joint venture with Korea's Xiji Biotech Co., Ltd. to research and innovate regenerative medicine fields such as cellular biomaterials. The registered capital is RMB 60 million, of which the company will invest 39.6 million yuan, accounting for 66%. Up to now, the company has completed the industrial and commercial registration procedures for the establishment of a new company. This foreign investment has been reviewed and approved by the company's general manager's office, and there is no need to submit it to the company's board of directors and shareholders' meeting for consideration. This foreign investment does not constitute a related transaction, nor does it constitute a major asset restructuring.

Sanyou Medical announced that the company plans to use its own capital to jointly invest in a new joint venture with Korea's Xiji Biotech Co., Ltd. to research and innovate regenerative medicine fields such as cellular biomaterials. The registered capital is RMB 60 million, of which the company will invest 39.6 million yuan, accounting for 66%. Up to now, the company has completed the industrial and commercial registration procedures for the establishment of a new company. This foreign investment has been reviewed and approved by the company's general manager's office, and there is no need to submit it to the company's board of directors and shareholders' meeting for consideration. This foreign investment does not constitute a related transaction, nor does it constitute a major asset restructuring.